BioNTech In Another China ADC Deal, This Time With Medilink

HER3-Targeting Asset

 
• By Dexter Jie Yan
  
unique
BioNTech picks Medilink’s differentiated TMALIN ADC platform in HER3-targeting ADC deal • Source: Shutterstock

More from China

More from Focus On Asia